Pharmaceuticals
Marking One Year Milestone, ADDI Expands Access to Global Data for Alzheimer's Researchers
Organization saw growth in AD Workbench users, data partners, and patient datasets from across the globe, including from low- and middle-income countries SEATTLE, Nov. 17, 2021 /PRNewswire/ -- Today, the Alzheimer's Disease Data Initiative (ADDI) marked one year of transforming how Alzheimer's d...
2021-11-17 19:00
3693
Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit
BEIJING and DURHAM, N.C., Nov. 17, 2021 /PRNewswire/ -- Brii Biosciences Limited
2021-11-17 18:52
5019
OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF
SINGAPORE, Nov. 17, 2021 /PRNewswire/ -- OncoOne
2021-11-17 09:10
3280
Recbio Receives Pharmaceutical Production License from Jiangsu Medical Products Administration for Production of COVID-19 Vaccine
TAIZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a biopharmaceutical company focusing on the research, development and commercialization of innovative vaccines that can address prevalent diseases with significant burdens, recently announced that the c...
2021-11-17 09:00
3295
Kira Pharmaceuticals Appoints Teri Loxam as Chief Operating Officer and Chief Financial Officer
CAMBRIDGE, Mass. and SUZHOU, Jiangsu, China, Nov. 16, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement-targeted therapies to treat immune-mediated diseases, today announced the appointment ofTeri Loxam as Chief Operating Officer (COO...
2021-11-16 19:00
2944
Advanced Sterilization Products' Global Commercial Leader, Nilesh Shah, sets sights on preventing HAIs in Asia
SINGAPORE, Nov. 16, 2021 /PRNewswire/ -- Advanced Sterilization Products' (ASP) recently appointed Vice President, General Manager and Global Commercial Leader, Nilesh Shah looks to strengthen ASP's footing in growing markets to improve healthcare standards by reducing the rate of healthcare-assoc...
2021-11-16 10:05
6563
Baxter Philippines launches My Kidney Journey portal to support patients with Chronic Kidney Disease
MANILA, Philippines, Nov. 16, 2021 /PRNewswire/ -- Baxter Asia Pacific (Baxter), a global leader in dialysis care, announced today the launch ofMy Kidney Journey, a comprehensive online portal to support patients living with Chronic Kidney Disease (CKD) inthe Philippines. Chronic Kidney Disease ...
2021-11-16 10:00
2113
Clinical Studies of PD-L1 Antibody ASC22 for HBV Functional Cure Selected for Inclusion in the "Best of The Liver Meeting's Summary" by AASLD Review Committee
-- Inclusion in the "Best of The Liver Meeting's Summary" is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB -- In patients with the baseline HBsAg level ≤ 500 IU/mL, the Phase IIb study demonstrated sustained HBsAg loss in 19...
2021-11-16 08:35
3627
Nanoform signs GMP agreement and achieves near-term business target
HELSINKI, Nov. 15, 2021 /PRNewswire/ -- Insider information Nanoform Finland Plc November 15, 2021 05:05 p.m. Finnish time / 04:05 p.m. Swedish time Nanoform signs GMP agreement and achieves near-term business target Helsinki, Finland - Nanoform, an innovative nanoparticle medicine enabling ...
2021-11-15 23:17
2267
R&D Milestone: HebaBiz Biotech's application for phase III clinical trial in China for Clevudine (L-FMAU), an anti-hepatitis B virus drug candidate under development has been approved
BEIJING, Nov. 15, 2021 /PRNewswire/ -- HebaBiz Biotech is pleased to announce that inNovember 2021, the Center for Drug Evaluation (CDE) of The National Medical Products Administration (NMPA) ofChina has approved the application for phase III clinical study of Clevudine (L-FMAU), a drug candidate...
2021-11-15 22:47
3466
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
- Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care - Top-line results for Part A of the study, designed to evaluate safety and tolerability of RHB-107 and dose sel...
2021-11-15 20:00
4487
Seegene Opens New Subsidiary in Bogotá, Colombia, to Advance Regional COVID-19 Testing
SEOUL, South Korea, Nov. 15, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading biotechnology firm specializing in molecular diagnostics (MDx), has announced the opening of an eighth global subsidiary, strategically located in Bogotá,Colombia. The new entity, known as 'Seegene Colombia S.A....
2021-11-15 19:00
2353
Gannex Announces China NMPA Approved Phase II and III Protocols of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis
SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the protocols of Phase II and III clinical trials of ASC42 to treat patients with primary biliary cholangitis (PBC) has been approved by China National ...
2021-11-15 08:30
3607
Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology
SAN FRANCISCO and SUZHOU, China, Nov. 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-11-15 08:00
3751
Treadwell Therapeutics Announces A Presentation at the 2021 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor
NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced a presentation for the Company's CFI-402411 program, an oral, first-in-class inhibitor ofHematopoietic Progenitor Kinase...
2021-11-13 02:56
5407
The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)
MINSK, Belarus, Nov. 12, 2021 /PRNewswire/ -- As an enterprise in CBIP, the New
Era Biotechnology Co., Ltd. participated in the fourth edition of the China
International Import Expo (CIIE) which opened inShanghai on November 5, 2021.
2021-11-12 09:11
2917
Hetero and Shenzhen Beimei Pharmaceuticals launch antiviral drug Oselavir® in China
Oseltamivir phosphate is used in the treatment of acute uncomplicated influenza infection in adults, adolescents and children BEIJING, Nov. 12, 2021 /PRNewswire/ -- Hetero, a globally renowned vertically integrated pharmaceutical organization and Shenzhen Beimei Pharmaceuticals jointly announced...
2021-11-12 09:00
4240
Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03
* Well tolerated and good safety profile, no SAE or TEAE leading to early discontinuation, no abnormal vital signs/laboratory testing results with clinical significance * 20μg ReCOV induced high titer of anti-SARS-CoV-2 neutralizing antibodies, with at least comparable level than published da...
2021-11-12 07:55
4319
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint
SHANGHAI, Nov. 11, 2021 /PRNewswire/ -- Everest Medicines and Gilead Sciences, Inc. (Nasdaq: GILD) jointly announces today that Everest Medicines sponsored (HKEX 1952.HK) Phase2b EVER-132-001 study of sacituzumab govitecan (marketed as Trodelvy® in the United States) met its primary endpoint o...
2021-11-11 08:05
4450
Ascletis Announces Approval of Phase II Clinical Trial of ASC22 (Envafolimab) by China NMPA for Immune Restoration/Functional Cure of HIV-1 Infected Patients
HANGZHOU, China and SHAOXING, China, Nov. 10, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the approval of the Phase II clinical trial of ASC22 (Envafolimab) by China National Medical Products Administration (NMPA) for the proposed new indication of immune restoration/fu...
2021-11-10 08:30
3881
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 320 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 317 media titles]
2026-08-27 10:25
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 310 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 305 media titles]
2026-09-01 11:00
Most Read
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
18398